| Literature DB >> 25329596 |
Taissia G Popova1, Virginia Espina1, Weidong Zhou1, Claudius Mueller1, Lance Liotta1, Serguei G Popov1.
Abstract
This study aimed to characterize a soluble proteome of popliteal lymph nodes during lymphadenitis induced by intradermal injection of Bacillus anthracis Sterne spores in mice using tandem LC-MS/MS and reverse-phase protein microarray with antibodies specific to epitopes of phosphorylated proteins. More than 380 proteins were detected in the normal intra-nodal lymph, while the infectious process resulted in the profound changes in the protein abundances and appearance of 297 unique proteins. These proteins belong to an array of processes reflecting response to wounding, inflammation and perturbations of hemostasis, innate immune response, coagulation and fibrinolysis, regulation of body fluid levels and vascular disturbance among others. Comparison of lymph and serum revealed 83 common proteins. Also, using 71 antibodies specific to total and phosphorylated forms of proteins we carried initial characterization of circulating lymph phosphoproteome which brought additional information regarding signaling pathways operating in the lymphatics. The results demonstrate that the proteome of intra-nodal lymph serves as a sensitive sentinel of the processes occurring within the lymph nodes during infection. The acute innate response of the lymph nodes to anthrax is accompanied by cellular damage and inflammation with a large number of up- and down-regulated proteins many of which are distinct from those detected in serum. MS data are available via ProteomeXchange with identifier PXD001342.Entities:
Mesh:
Substances:
Year: 2014 PMID: 25329596 PMCID: PMC4203832 DOI: 10.1371/journal.pone.0110873
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Figure 1Analyses of popliteal LNs in B. anthracis-infected mice two days post challenge vs. uninfected mice.
(A, B) H&E-stained sections of formalin-fixed LN tissue from uninfected (A) and infected (B) animals. Top panels show global views. Bottom panels show expanded views of regions identified by squares and demonstrate changes in the histopathology of cortical LN region. Tissue edema (green arrows) and numerous pyknotic cells (black arrows) are visible. Infiltrating neutrophils immunostained brown for myeloperoxidase (red arrows) are present. (C, D) Sections of formalin-fixed LN tissue from infected (D) and uninfected (C) mice immunostaned with rabbit anti-B. anthracis serum followed by secondary fluorescently-labelled antibody show accumulation of a large number of green-fluorescent bacteria (arrows) in the subcapsular region of LN of infected mouse. Fluorescence was detected at 495/520 nm using Olympus BX51 microscope. No increased subcapsular staining was found in control animals. The pictures represent typical observation obtained from ≥3 infected mice. (E) Bacterial counts in LNs of infected mice after plating of the homogenized tissue onto LB agar. Error bars represent SD of mean (n = 3 for days 0 to 3; n = 1 for day 4).
Figure 2Pie charts of the protein content (A, B) and top-scoring processes (C, D) in LNs of naïve and B. anthracis-infected mice.
(A) LN soluble proteome of spore-challenged mice contains a large number of proteins which appeared in LNs of during infection but were undetectable in naïve mice. (B) Infection up- or down-regulated a majority of LN proteins. Only 11 proteins showed no change in abundance. (C, D) KEGG analysis revealed cellular pathways relevant to LN proteins which were up-regulated (C) or down-regulated (D) by infection. Figures in the charts indicate the number of proteins in a particular category or pathway.
DAVID-based analysis of enriched processes for proteins up-regulated in infection.
| GO term for enriched process | Count | Fold Enrichment | |
| 1 | GO:0006957∼complement activation, alternative pathway | 5 | 19.2 |
| 2 | GO:0050818∼regulation of coagulation | 6 | 11.5 |
| 3 | GO:0032956∼regulation of actin cytoskeleton organization | 16 | 10.2 |
| 4 | GO:0042743∼hydrogen peroxide metabolic process | 5 | 9.6 |
| 5 | GO:0007599∼hemostasis | 17 | 9.2 |
| 6 | GO:0002526∼acute inflammatory response | 19 | 9 |
| 7 | GO:0043254∼regulation of protein complex assembly | 14 | 8.3 |
| 8 | GO:0031099∼regeneration | 5 | 8.3 |
| 9 | GO:0006418∼tRNA aminoacylation for protein translation | 9 | 7.5 |
| 10 | GO:0006956∼complement activation | 7 | 7.5 |
| 11 | GO:0050878∼regulation of body fluid levels | 17 | 7.3 |
| 12 | GO:0034097∼response to cytokine stimulus | 6 | 7.2 |
| 13 | GO:0042311∼vasodilation | 5 | 7.1 |
| 14 | GO:0006879∼cellular iron ion homeostasis | 5 | 6.6 |
| 15 | GO:0044087∼regulation of cellular component biogenesis | 15 | 6.5 |
| 16 | GO:0065004∼protein-DNA complex assembly | 12 | 6.1 |
| 17 | GO:0006007∼glucose catabolic process | 8 | 5.9 |
| 18 | GO:0051494∼negative regulation of cytoskeleton organization | 7 | 5.6 |
| 19 | GO:0050880∼regulation of blood vessel size | 7 | 5.6 |
| 20 | GO:0034622∼cellular macromolecular complex assembly | 31 | 5.5 |
| 21 | GO:0003018∼vascular process in circulatory system | 7 | 5.4 |
| 22 | GO:0000302∼response to reactive oxygen species | 5 | 5.3 |
| 23 | GO:0033043∼regulation of organelle organization | 21 | 5.2 |
| 24 | GO:0006959∼humoral immune response | 7 | 5 |
| 25 | GO:0006323∼DNA packaging | 12 | 4.6 |
| 26 | GO:0009611∼response to wounding | 41 | 4.5 |
| 27 | GO:0006954∼inflammatory response | 24 | 4.1 |
| 28 | GO:0045087∼innate immune response | 11 | 3.9 |
| 29 | GO:0051604∼protein maturation | 9 | 3.6 |
| 30 | GO:0006461∼protein complex assembly | 20 | 3.4 |
| 31 | GO:0051129∼negative regulation of cellular component organization | 8 | 3.3 |
| 32 | GO:0010564∼regulation of cell cycle process | 6 | 3.2 |
| 33 | GO:0006399∼tRNA metabolic process | 9 | 3.1 |
| 34 | GO:0006979∼response to oxidative stress | 7 | 3.1 |
| 35 | GO:0009719∼response to endogenous stimulus | 14 | 2.9 |
| 36 | GO:0005996∼monosaccharide metabolic process | 11 | 2.2 |
| 37 | GO:0019725∼cellular homeostasis | 20 | 2.2 |
| 38 | GO:0010033∼response to organic substance | 28 | 2.1 |
| 39 | GO:0042592∼homeostatic process | 28 | 1.8 |
| 40 | GO:0006508∼proteolysis | 38 | 1.4 |
*Count refers to a number of genes identified in a corresponding term. Terms with less than 5 genes identified were excluded from analysis.
**Enrichment value calculated by DAVID is a measure of probability (in –log scale) for members of a particular annotation cluster to be grouped together (for further explanation see Materials and Methods).
Figure 3KEGG maps illustrating selected pathways relevant to the soluble protein content of LNs in B. anthracis-infected mice.
Lists of proteins up- or down-regulated in LNs during infection (Table S2) were used as an input for KEGG software, which contains a database of pathway maps reflecting different biological processes. Red stars indicate the LN proteins mapped to the corresponding pathway using the following parameters: Fisher exact p value for enrichment probability ≤0.05 (strongly enriched), and a minimal number of proteins mapped to the pathway ≥5.
Proteins from naïve and B. anthracis-infected mice common between serum and lymph ranked according to their abundance in lymph during infection.
| Protein | GI number | Average spectral hits | |||
| Naïve serum | Naïve lymph** | Infected lymph*** | |||
| 1 | albumin | 148673375 | 457.5 | 214.5 | 375.75 |
| 2 | transferrin | 20330802 | 166 | 55 | 78.625 |
| 3 | serine (or cysteine) proteinase inhibitor,clade A, member 3K | 15079234 | 51 | 24.5 | 53.625 |
| 4 | parvalbumin | 31980767 | 1.5 | 57 | 47.5 |
| 5 | complement component 3 | 28175786 | 177.5 | 16.5 | 33.375 |
| 6 | hemopexin | 18044757 | 28 | 21 | 26.25 |
| 7 | serine (or cysteine) proteinase inhibitor,clade A, member 1b | 76881807 | 19 | 12.5 | 18.25 |
| 8 | apolipoprotein A-I | 2145141 | 82 | 8.5 | 17.75 |
| 9 | plasminogen | 200403 | 8 | 3 | 17.625 |
| 10 | hemoglobin, beta adult major chain | 31982300 | 311 | 11.5 | 16.5 |
| 11 | vitamin D-binding protein | 51172612 | 28 | 7.5 | 13 |
| 12 | adenylate kinase 1 | 10946936 | 2.5 | 21 | 11.875 |
| 13 | haptoglobin | 8850219 | 8 | 0 | 9.75 |
| 14 | alpha-2-HS-glycoprotein | 7304875 | 30 | 6 | 9.625 |
| 15 | alpha-1-antitrypsin 1–1 isoform 1 precursor | 6678079 | 1.5 | 4 | 9.375 |
| 16 | murinoglobulin 1 | 31982171 | 16 | 12 | 8.5 |
| 17 | esterase 1 | 553910 | 17.5 | 4 | 7.25 |
| 18 | coagulation factor II | 6753798 | 16.5 | 0 | 6 |
| 19 | complement factor B | 218156291 | 8 | 1.5 | 5.5 |
| 20 | inter alpha-trypsin inhibitor,heavy chain 4 | 226531047 | 13.5 | 1.5 | 5.5 |
| 21 | hemoglobin alpha 1 chain | 145301578 | 215 | 0.5 | 5.25 |
| 22 | apolipoprotein E | 20381029 | 24 | 2 | 5.125 |
| 23 | CAP, adenylate cyclase-associated protein 1 | 157951604 | 13.5 | 0 | 4 |
| 24 | fatty acid binding protein 4, adipocyte | 14149635 | 3 | 0 | 3.875 |
| 25 | glyoxalase 1 | 148676704 | 1.5 | 2 | 3.625 |
| 26 | coactosin-like 1 | 19482160 | 2 | 1.5 | 3.125 |
| 27 | serine (or cysteine) proteinase inhibitor, clade C (antithrombin), member 1 | 18252782 | 27 | 1 | 2.625 |
| 28 | hypothetical protein LOC71775 | 21313642 | 7.5 | 0 | 2.625 |
| 29 | peroxiredoxin 5 precursor | 6755114 | 5 | 0 | 2.5 |
| 30 | Rho, GDP dissociation inhibitor (GDI) beta | 33563236 | 2 | 0 | 2.5 |
| 31 | kininogen 1 | 12963497 | 16.5 | 0 | 2.375 |
| 32 | serum amyloid A 1 | 6677843 | 2 | 0.5 | 2.25 |
| 33 | histidine-rich glycoprotein | 11066003 | 14 | 0 | 2 |
| 34 | gelsolin | 28916693 | 14 | 0 | 1.875 |
| 35 | peptidylprolyl isomerase A | 6679439 | 2.5 | 0 | 1.5 |
| 36 | cell division cycle 42 homolog | 6753364 | 1.5 | 0 | 1.5 |
| 37 | serine (or cysteine) proteinase inhibitor,clade A, member 6 | 6680856 | 11.5 | 0 | 1.375 |
| 38 | UMP-CMP kinase | 165377065 | 1 | 6 | 1.375 |
| 39 | vitronectin | 6755987 | 10 | 0 | 1.25 |
| 40 | actin related protein 2/3complex, subunit 3 | 9790141 | 4 | 0 | 1.25 |
| 41 | peroxiredoxin 2 | 148747558 | 34 | 0.5 | 1.25 |
| 42 | kininogen 2 | 41235784 | 5 | 0.5 | 1.25 |
| 43 | inter-alpha trypsin inhibitor,heavy chain 2 | 226874935 | 1.5 | 0 | 1.125 |
| 44 | paraoxonase 1 | 15215219 | 17 | 0 | 1.125 |
| 45 | myosin light chain, regulatory B-like | 71037403 | 2.5 | 1 | 1.125 |
| 46 | destrin | 9790219 | 5 | 0 | 1 |
| 47 | selenoprotein P precursor | 74271806 | 1.5 | 0 | 1 |
| 48 | glutathione peroxidase 1 | 84871986 | 7.5 | 0.5 | 1 |
| 49 | serine (or cysteine) proteinaseinhibitor, clade A, member 3G | 86476056 | 8.5 | 0 | 0.875 |
| 50 | complement component 9 | 15375312 | 7 | 0 | 0.75 |
| 51 | phosphatidylethanolaminebinding protein 1 | 84794552 | 2 | 1 | 0.75 |
| 52 | alpha 1 microglobulin/bikunin | 6680684 | 0.5 | 0.5 | 0.625 |
| 53 | serum amyloid P-component | 226958497 | 6.5 | 0 | 0.625 |
| 54 | hemoglobin, beta adult minor chain | 17647499 | 200 | 0.5 | 0.625 |
| 55 | myoglobin | 21359820 | 15.5 | 0 | 0.625 |
| 56 | acid phosphatase 1, soluble | 31542070 | 1 | 0.5 | 0.625 |
| 57 | fibrinogen, alpha polypeptide | 33563252 | 7 | 0 | 0.625 |
| 58 | nucleoside-diphosphate kinase 1 | 37700232 | 6.5 | 0 | 0.625 |
| 59 | carboxypeptidase N,polypeptide 2 homolog | 147904569 | 8 | 0 | 0.625 |
| 60 | peroxiredoxin 1 | 6754976 | 1.5 | 0.5 | 0.5 |
| 61 | alpha-2-glycoprotein 1, zinc | 148687277 | 7.5 | 0 | 0.5 |
| 62 | SH3 domain bindingglutamic acid-richprotein-like 3 | 18017602 | 1.5 | 0 | 0.5 |
| 63 | acylphosphatase 2, muscle type | 27229219 | 1.5 | 0.5 | 0.5 |
| 64 | beta-2-microglobulin | 31981890 | 7 | 0 | 0.5 |
| 65 | cofilin 1, non-muscle | 6680924 | 22.5 | 0.5 | 0.375 |
| 66 | calponin 2 | 6680952 | 3.5 | 0 | 0.375 |
| 67 | cysteine and glycine-richprotein 1 | 6681069 | 1 | 0.5 | 0.375 |
| 68 | alpha-crystallin B chain | 6753530 | 1.5 | 0 | 0.375 |
| 69 | proteosome (prosome, macropain)subunit, beta type 8(large multifunctional protease 7) | 158303322 | 3.5 | 0 | 0.375 |
| 70 | thioredoxin 1 | 6755911 | 3.5 | 0.5 | 0.375 |
| 71 | apolipoprotein A-II | 157951676 | 16.5 | 4.5 | 0.375 |
| 72 | lysozyme | 8393739 | 1.5 | 0 | 0.375 |
| 73 | apolipoprotein C-III | 15421856 | 118 | 0.5 | 0.375 |
| 74 | ADP-ribosylation factor 3 | 6680718 | 2.5 | 0 | 0.25 |
| 75 | ADP-ribosylation factor 5 | 6680722 | 1 | 0 | 0.25 |
| 76 | macrophage migration inhibitory factor | 6754696 | 2 | 0 | 0.25 |
| 77 | adipsin | 7304867 | 1.5 | 0.5 | 0.25 |
| 78 | protease, serine, 1 | 16716569 | 15.5 | 0.5 | 0.25 |
| 79 | proteasome(prosome, macropain)subunit, beta type 2 | 148698332 | 4.5 | 0 | 0.25 |
| 80 | superoxide dismutase 1, soluble | 45597447 | 2 | 0 | 0.25 |
| 81 | serum amyloid A 4 | 6755398 | 31.5 | 0 | 0.25 |
| 82 | fatty acid bindingprotein 5, epidermal | 6754450 | 3 | 0.5 | 0.125 |
| 83 | magnesium-dependentphosphatase-1 | 12963663 | 1 | 0.5 | 0 |
*Average from 3 mice; **Average from 4 mice; ***Average per day for LN samples collected at days 1 to 4 post challenge (4 mice per sample at days 1 to 3, one sample at day 4).
Relative abundance of phosphoproteins and related signaling proteins in lymph of infected mice in comparison with naïve mice.
| Up-regulated | Down-regulated | ||||||||
| Protein | Day1 | Day2 | Day3 | Aver-ageper day | Protein | Day1 | Day2 | Day3 | Aver-ageper day |
|
| |||||||||
| Stat1(Tyr701) | 2.19 | 3.72 | 6.82 | 4.24 | Stat6(Tyr641) | 0.86 | 0.75 | 0.70 | 0.77 |
| Stat3(Tyr705) | 3.13 | 4.53 | 4.94 | 4.20 | Jak1(Tyr1022/Tyr1023) | 1.04 | 0.73 | 0.50 | 0.76 |
| Stat1 | 1.82 | 2.62 | 3.15 | 2.53 | ATF2(Thr69/Thr71) | 0.68 | 0.57 | 0.56 | 0.61 |
| Stat3(Ser727) | 1.20 | 1.99 | 2.08 | 1.76 | HMGA1 | 0.70 | 0.39 | 0.18 | 0.42 |
| CREB(Ser133) | 1.07 | 1.77 | 1.91 | 1.59 | |||||
| IkappaB alpha | 1.33 | 1.58 | 1.54 | 1.48 | |||||
| Stat6 | 1.25 | 1.67 | 1.36 | 1.43 | |||||
| NF-kappaB p65(Ser536) | 1.18 | 1.40 | 1.30 | 1.29 | |||||
| Stat5(Tyr694) | 1.07 | 1.38 | 1.33 | 1.26 | |||||
| Stat5 | 1.17 | 1.40 | 1.14 | 1.23 | |||||
|
| |||||||||
| S6 Ribosomal Protein (Ser240/Ser244) | 1.67 | 3.13 | 2.67 | 2.49 | p70 S6 Kinase (Thr389) | 1.00 | 0.84 | 0.93 | 0.92 |
| S6 Ribosomal Protein (Ser235/Ser236) | 1.58 | 3.00 | 2.32 | 2.30 | SAPK/JNK(Thr183/Tyr185) | 0.48 | 0.28 | 0.28 | 0.35 |
| ERK 1/2 | 1.50 | 1.96 | 2.10 | 1.85 | ERK1/2(Thr202/Tyr204) | 0.49 | 0.31 | 0.19 | 0.33 |
| Proteosome 20S | 1.36 | 1.90 | 2.08 | 1.78 | p38 MAP Kinase (Thr180/Tyr182) | 0.42 | 0.13 | 0.19 | 0.25 |
| p38 MAP Kinase | 1.03 | 1.45 | 1.44 | 1.31 | HSP27(Ser82) | 0.59 | 0.38 | 0.29 | 0.42 |
| p70 S6 Kinase (Ser371) | 1.02 | 1.27 | 1.50 | 1.27 | |||||
|
| |||||||||
| Caspase 7 cleaved (Asp198) | 1.49 | 2.16 | 2.85 | 2.17 | Bim | 0.80 | 0.96 | 0.89 | 0.88 |
| Survivin | 1.58 | 2.24 | 2.41 | 2.08 | XIAP | 0.58 | 0.37 | 0.45 | 0.47 |
| PARP cleaved (Asp214) | 1.49 | 1.67 | 2.05 | 1.74 | TNF R1 | 0.60 | 0.33 | 1.22 | 0.72 |
| Caspase 3 cleaved (Asp175) | 1.41 | 1.77 | 1.73 | 1.64 | |||||
| Beclin1 | 1.35 | 1.66 | 1.76 | 1.59 | |||||
| LC3B | 1.43 | 1.69 | 1.62 | 1.58 | |||||
| Bad | 1.11 | 1.81 | 1.48 | 1.47 | |||||
| Bax | 1.20 | 1.50 | 1.34 | 1.34 | |||||
| Caspase 9 cleaved (Asp330) | 1.07 | 1.22 | 1.49 | 1.26 | |||||
| Puma | 1.19 | 1.32 | 1.24 | 1.25 | |||||
| FADD(Ser194) | 0.95 | 1.16 | 1.36 | 1.16 | |||||
| Bcl-xL | 0.94 | 1.44 | 1.04 | 1.14 | |||||
| Caspase 8 | 1.15 | 1.21 | 0.94 | 1.10 | |||||
|
| |||||||||
| AKT | 1.26 | 1.83 | 1.80 | 1.63 | Akt(Ser473) | 0.99 | 0.92 | 0.40 | 0.77 |
| SHP1(Tyr1020) | 1.58 | 1.75 | 1.86 | 1.73 | GSK3 alpha/beta (Ser21/Ser9) | 1.05 | 0.95 | 0.80 | 0.93 |
| INPP4 | 1.74 | 2.39 | 2.32 | 2.15 | |||||
| PTEN | 1.23 | 1.73 | 1.75 | 1.57 | |||||
|
| |||||||||
| Src(Tyr527) | 1.02 | 1.34 | 0.90 | 1.09 | Src(Tyr416) | 0.65 | 0.58 | 0.34 | 0.52 |
| Lck(Tyr505) | 1.28 | 1.17 | 1.36 | 1.27 | |||||
|
| |||||||||
| Myeloperoxidase | 1.20 | 1.57 | 1.51 | 1.42 | TLR9 | 0.85 | 0.90 | 0.75 | 0.83 |
| CD68 | 1.23 | 1.32 | 1.14 | 1.23 | Ras-GRF1(Ser916) | 0.72 | 0.74 | 0.44 | 0.63 |
| Sumo 1 | 1.10 | 1.36 | 1.15 | 1.20 | eNOS(Ser1177) | 0.76 | 0.72 | 0.55 | 0.68 |
| Sumo 2/3 | 1.10 | 1.25 | 1.51 | 1.29 | |||||
| IL-10 | 1.07 | 1.09 | 0.99 | 1.05 | |||||
*Mean protein abundance in infected relative to uninfected mice. Protein extracts from 3 individual LNs were analyzed at each time point.
**Deviation of mean (95% confidence interval) calculated across all proteins in the Table is ≤0.098. The proteins demonstrating changes of mean less than 0.098 were: SAPK/JNK, Bad, FLIP, eNOS(Ser113), IL-10, HSP90, p53 (Ser115).
Figure 4Cancer Landscape (Cscape) Protein Pathway Activation map of lymph from popliteal LN of mice infected with B. anthracis at day 2 post infection based on RPMA data.
Increase and decrease in signaling are shown in increasing shades of red or green respectively. Each balloon pin is placed over the protein measured. Magnified view of the ERK and JNK in Ras pathway (green box) and STAT in cytokine signaling pathway (red box) are shown to reveal pathway details.